List of Acuvue Theravision With Ketotifen drug patents
Acuvue Theravision With Ketotifen is owned by Johnson Johnson Visn.
Acuvue Theravision With Ketotifen contains Ketotifen Fumarate.
Acuvue Theravision With Ketotifen has a total of 2 drug patents out of which 0 drug patents have expired.
Acuvue Theravision With Ketotifen was authorised for market use on 25 February, 2022.
Acuvue Theravision With Ketotifen is available in drug-eluting contact lens ;ophthalmic dosage forms.
The generics of Acuvue Theravision With Ketotifen are possible to be released after 27 June, 2030.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9474746 | JOHNSON JOHNSON VISN | Methods for stabilizing oxidatively unstable compositions |
Mar, 2028
(5 years from now) | |
| US9962376 | JOHNSON JOHNSON VISN | Methods and ophthalmic devices used in the treatment of ocular allergies |
Jun, 2030
(7 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Product (NP) | Feb 25, 2025 |
Drugs and Companies using KETOTIFEN FUMARATE ingredient
Market Authorisation Date: 25 February, 2022
Treatment: NA
Dosage: DRUG-ELUTING CONTACT LENS ;OPHTHALMIC
ACUVUE THERAVISION WITH KETOTIFEN family patents
11
United States
6
European Union
4
Korea, Republic of
3
Hong Kong
3
Russia
3
Canada
3
China
2
Taiwan, Province of China
2
Japan
2
Australia
2
Argentina
2
Spain
2
Brazil
1
Hungary
1
Singapore
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic